28 - Fentanyl transdermal system  pp. 134-136

Fentanyl transdermal system

By Hamid Nourmand

Image View Previous Chapter Next Chapter

Generic Name: fentanyl transdermal system

Trade/Proprietary Name: Duragesic™

Drug Class: opioid analgesic (Schedule II)

Manufacturer: Ortho-McNeil Division of Johnson & Johnson Inc., Raritan, NJ 08869

Chemical Structure: see Figure 28.1

Chemical Name:N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl) propanamide


Fentanyl transdermal system (Duragesic™) is a rectangular transdermal patch containing a high concentration of fentanyl, a potent, short-acting Schedule II opioid agonist. Fentanyl transdermal system (FTS) provides a continuous systemic delivery of fentanyl for 72 hours, and offers additional benefits including prolonged and uniform analgesic effect as well as reduced adulteration and abuse potential. The FTS includes a drug reservoir that contains fentanyl in a gel matrix, a release membrane that allows time- and surface-limited absorption of the drug, and an adhesive backing that ensures that the preparation attaches firmly to skin (Figure 28.2).

Mode of activity

Fentanyl interacts predominantly with the mu receptors in the brain and spinal cord to produce analgesia, euphoria, and dysphoria. Because of its low molecular weight, high potency and lipid solubility, fentanyl is an ideal agent for transdermal application. Soon after application of the patch to the intact skin, a fentanyl depot concentrates in the subcutaneous fat, and it is then gradually released to the systemic circulation. Peak plasma concentration is reached between 24 and 72 hours of the treatment.

Bernstein K . Inappropriate use of transdermal fentanyl for acute postoperative pain. J Oral Maxillofac Surg 1994;52: 896.
Horton R , Barber C . Opioid-induced respiratory depression resulting from transdermal fentanyl-clarithromycin drug interaction in a patient with advanced COPD. J Pain Symptom Manage 2009;37:2–5.
Payne R , Mathias SD , Pasta DJ , et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998;16:1588–1593.